Lantern Pharma Inc.
LTRN
We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercializ…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$14M
▲ +17.6% YoY
Op. Margin
–
ROIC
-448.75%
▼ -45.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$13M
▲ +12.0% YoY
Op. Cash Flow (TTM)
-$13M
▲ +12.0% YoY
Net Debt
-$8M
Net Cash Position
Cash & Equiv.
$8M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with LTRN
Held by ETFs
LTRN is in 1 US ETF. The largest of them, with LTRN's weight in each:
Lantern Pharma (LTRN) in two numbers
Questions about Lantern Pharma
Does Lantern Pharma (LTRN) pay a dividend?
No. Lantern Pharma (LTRN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 9 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in LTRN's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing LTRN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.